a maker of medical devices and glucose monitoring systems
Industry MedicalNursingServices
This is a Bearish indicator signaling DXCM's price could decline from here. Traders may explore shorting the stock or put options. A.I. dvisor identified 46 similar cases where DXCM's MACD histogram became negative, and of them led to successful outcomes. Odds of Success:
DXCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 25 of 35 cases where DXCM's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 71%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DXCM's RSI Indicator exited the oversold zone, 22 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +1.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in 200 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DXCM as a result. In 58 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
The Moving Average Convergence Divergence Histogram (MACD) for DXCM turned negative on November 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 33 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
DXCM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for DXCM entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 27 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.431) is normal, around the industry mean (4.142). P/E Ratio (30.779) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.332) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.988) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DexCom shares have drifted lower over the past month, giving back a portion of the gains that followed a strong second-quarter earnings report. After trading near $89 in mid-September, the stock has declined roughly 9.4% to trade around $80, marking one of the weaker stretches for the shares in recent months.
The move has come against a backdrop of uneven sentiment across the medical devices sector, where concerns over healthcare policy, tougher year-over-year comparisons, and a volatile macro environment have weighed on valuations. Even so, the analyst community has largely remained constructive on DexCom, with several firms raising price targets or initiating coverage in October. That disconnect — solid fundamentals and improving sell-side sentiment versus a softening share price — frames the current setup ahead of the company's next earnings release.
DexCom, Inc. is a San Diego–based medical technology company that pioneered and now leads the market for continuous glucose monitoring (CGM) systems. Founded in 1999, the company designs, manufactures, and markets wearable sensors that deliver real-time glucose readings to smartphones and smartwatches, helping people with diabetes and their care teams manage the condition more effectively.
The company's product portfolio centers on its Dexcom G6, G7, and G7 15 Day CGM systems, alongside Stelo, the first over-the-counter CGM cleared by the U.S. Food and Drug Administration. DexCom is also advancing a next-generation G8 platform and expanding internationally, where it has posted faster growth than in its core U.S. market. Investors follow the stock for its recurring, sensor-driven revenue model, expanding margins, and its position as a leader in a category with a large, underpenetrated addressable population.
DexCom's most recent earnings report, released in late July for the second quarter of 2026, showed revenue of about $1.31 billion, up 13% year over year, with U.S. revenue up 11% and international revenue up 19%. The company raised the low end of its full-year revenue outlook to a range of $5.18 billion to $5.25 billion and lifted margin guidance, and the stock rose roughly 8% in the following session.
Since then, the focus has shifted to product expansion and the broader CGM competitive landscape. In June 2026, the FDA cleared the Stelo sensor for children, making it the first over-the-counter CGM available for pediatric prediabetic and diabetic patients. DexCom also presented data from its CONNECT trial at the 2026 American Diabetes Association Scientific Sessions, showing meaningful A1C reductions in people with type 2 diabetes not using insulin.
In October, sell-side activity picked up. Barclays initiated coverage with an Overweight rating and a $115 price target, while BTIG raised its target to $96 from $90, Mizuho to $100 from $95, and RBC to $105, each citing growth potential in the CGM market. Analysts have also flagged potential headwinds, including tougher revenue comparisons and procedure-volume pressures tied to Affordable Care Act and Medicaid policy shifts.
Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing artificial intelligence trading bots. While Tickeron offers hundreds of AI-driven bots that trade thousands of tickers across a range of strategies and timeframes, only the most relevant and consistently strong performers appear in this featured section. Each bot follows its own approach, with different risk profiles, holding periods, and performance metrics, giving traders a way to explore automated strategies that align with their objectives. Browsing the trending list can help investors identify which AI signals are currently attracting attention in the market.
Looking ahead, DexCom's guidance calls for revenue of $5.18 billion to $5.25 billion in 2026, or roughly 11% to 13% growth, supported by continued adoption of the G7 15 Day sensor, the expansion of Stelo, and further international penetration. Over the longer term, the company has outlined targets through 2030 that include annual organic growth exceeding 10% and meaningful gross and operating margin expansion.
Investors will be watching several factors closely: the pace of G7 15 Day adoption, progress on the G8 platform, the competitive response from Abbott's FreeStyle Libre franchise and Medtronic, and any shifts in reimbursement or healthcare policy. Macro conditions — including interest rates and broader market volatility — as well as the October 29 earnings release, will also shape sentiment in the near term. As always, the company's ability to sustain double-digit growth while defending its margins will be central to the stock's trajectory.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.